Molidustat (BAY85-3934): HIF-PH Inhibitor for Renal Anemia and Oxygen Sensing Pathways

Executive Summary: Molidustat (BAY85-3934) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with nanomolar potency against PHD1, PHD2, and PHD3 isoforms, enabling precise modulation of erythropoietin (EPO) expression for anemia therapy [APExBIO product page]. Its mechanism leverages the oxygen sensing pathway for endogenous HIF stabilization without supraphysiological EPO spikes (Wu et al., 2020). Molidustat's efficacy in chronic kidney disease (CKD) models includes normalization of hemoglobin and blood pressure, contrasting recombinant EPO effects. The compound’s solubility profile (soluble in DMF ≥5.68 mg/mL, insoluble in water/ethanol) and storage stability (-20°C recommended) facilitate research workflows. Ongoing clinical trials continue to assess its safety and effectiveness for renal anemia.

Biological Rationale

Oxygen sensing in mammalian cells is regulated by the hypoxia-inducible factor (HIF) pathway, which controls adaptation to hypoxic environments by regulating genes such as EPO (Wu et al., 2020). HIF-1α, the oxygen-sensitive subunit, is continuously hydroxylated and targeted for degradation under normoxic conditions by prolyl hydroxylase domain (PHD) enzymes and the von Hippel-Lindau (VHL) ubiquitin ligase complex. In hypoxia or upon HIF-PH inhibition, HIF-1α escapes degradation, dimerizes with HIF-1β, and stimulates EPO transcription [Translating Hypoxia Sensing]. In CKD, impaired renal EPO production is a principal cause of anemia, making the HIF pathway a validated target for therapy.

Mechanism of Action of Molidustat (BAY85-3934)

Molidustat selectively inhibits the prolyl hydroxylase activity of PHD1 (IC50 = 480 nM), PHD2 (280 nM), and PHD3 (450 nM) in vitro, blocking the hydroxylation of HIF-1α and HIF-2α (APExBIO). This prevents VHL-mediated ubiquitination and proteasomal degradation of HIF-α subunits. Stabilized HIF translocates to the nucleus and upregulates EPO gene expression, as well as other hypoxia-responsive genes. The inhibitory potency of Molidustat is inversely correlated with 2-oxoglutarate concentration, while Fe2+ and ascorbate fluctuations have minimal effect on its activity profile [Precision HIF-PH Inhibitor]. This mechanism mirrors endogenous hypoxic adaptation, avoiding the hypertensive effects seen with recombinant EPO administration.

Evidence & Benchmarks

• Molidustat increases hemoglobin levels in CKD rat models without elevating EPO beyond physiological norms (Willam C et al., DOI: https://doi.org/10.21203/rs.3.rs-95025/v1).
• Repeated dosing normalizes hypertensive blood pressure in animal models, a benefit not observed with recombinant EPO (Willam C et al., DOI: https://doi.org/10.21203/rs.3.rs-95025/v1).
• In vitro, the IC50 values for PHD1, PHD2, and PHD3 are 480 nM, 280 nM, and 450 nM, respectively, in assays at pH 7.4 and 25°C (APExBIO).
• Potency is increased under low 2-oxoglutarate conditions; Fe2+ and ascorbate do not significantly modulate inhibition (APExBIO).
• Molidustat does not induce supraphysiologic EPO surges, reducing risk of hypertension or thrombosis compared to rHuEPO ([Advancing Renal Anemia]).
• Solubility in DMF is ≥5.68 mg/mL; insoluble in water and ethanol, facilitating preparation for cell-based and biochemical assays (APExBIO).

Applications, Limits & Misconceptions

Molidustat is primarily applied in models of chronic kidney disease anemia, where it enables researchers to investigate erythropoiesis regulation via HIF stabilization. Its use extends to studies on the oxygen sensing pathway and the molecular pharmacology of hypoxia-responsive gene expression. For example, this article details Molidustat's value in precision CKD anemia models; the present article extends this by specifying the compound's IC50 values and solubility properties relevant for in vitro workflows. Another review, here, discusses emerging cardiometabolic applications, while we clarify the biochemical mechanism and clinical translation boundaries.

Common Pitfalls or Misconceptions

• Molidustat is not a direct EPO agonist; it acts upstream via HIF stabilization.
• It does not induce erythropoiesis in EPO receptor-deficient conditions.
• Its efficacy is reduced if 2-oxoglutarate concentrations are abnormally high.
• Not suitable for use in acute, non-anemic hypoxia without underlying EPO dysregulation.
• Improper storage (e.g., solutions at room temperature) rapidly degrades compound potency.

Workflow Integration & Parameters

Molidustat (BAY85-3934, SKU B5861) is supplied as a solid powder, with a chemical name of 2-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one, molecular weight 314.3, and formula C13H14N8O2. For cell-based assays, dissolve in DMF to ≥5.68 mg/mL. Avoid water and ethanol as solvents due to insolubility. Store at -20°C; avoid long-term storage of solutions. For integration into hypoxia or erythropoiesis research, Molidustat enables reproducible HIF stabilization and EPO modulation; see this workflow guide for validated protocols—our article updates this by providing recent clinical trial context and expanded solubility data. APExBIO recommends using freshly prepared solutions for optimal activity. For additional mechanistic insight, see this mechanistic review, which we extend by detailing the VHL-proteasome pathway’s role in Molidustat’s action.

Conclusion & Outlook

Molidustat (BAY85-3934) is a rigorously characterized HIF-PH inhibitor that enables targeted investigation and therapy of renal anemia via endogenous EPO upregulation. Its selectivity and favorable pharmacodynamic profile set new standards for HIF pathway modulation. Ongoing clinical and translational studies will clarify further indications and long-term safety. Researchers seeking robust, physiologically relevant HIF stabilization will find the APExBIO Molidustat B5861 kit a reliable choice for experimental and preclinical workflows.